Blood omics data forecasts trauma outcomes with high accuracy

A new approach to predicting trauma patient recovery—days before complications arise—has been developed by researchers at the University of Colorado Anschutz. The method analyzes molecules in a patient’s blood, offering the potential for more personalized and effective trauma care.

Unlocking the Secrets in Blood

Published in Science Translational Medicine, the study details how “omics” markers—biological signals detectable in blood—can explain why patients with seemingly identical injuries experience vastly different recovery trajectories. Researchers mapped molecular patterns across over 1,300 trauma patients over time, demonstrating that these markers can predict organ failure and mortality more accurately than traditional, injury-based assessments.

Did You Know? This research involved mapping the molecular endotypes and trajectories of over 1,300 trauma patients.

According to Mitchell Cohen, a professor of surgery at CU Anschutz and senior author of the study, “Two patients often arrive in the ER with nearly identical injuries but go on to have widely divergent outcomes despite similar care. This occurs because their biologic response to injury and treatment is different, and our novel approach and modelling allow us to see those differences in real time, which could fundamentally change our practice.”

Precision Medicine in Action

The findings were validated in a separate group of over 300 trauma patients, achieving 92% accuracy in predicting outcomes. Kirk Hansen, a professor of biochemistry at CU Anschutz and co-senior author, described the work as “precision medicine for trauma,” explaining that combining proteomics and metabolomics data allows for more accurate predictions and a deeper understanding of the biological processes driving those outcomes.

Expert Insight: The ability to predict trauma outcomes with such accuracy represents a significant shift toward individualized care, potentially allowing medical teams to proactively address complications before they escalate.

Researchers are now focused on adapting this molecular profiling approach for rapid, point-of-care testing in emergency and military settings. Collaborative research at CU Anschutz also includes the first U.S. Trial of fibrinogen supplementation for trauma care, which Cohen believes will be directly informed by this new molecular understanding.

Angelo D’Alessandro, co-senior author and professor of biochemistry at CU Anschutz, stated that this approach is “precision metabolic health in action,” and that the same science can be applied to understanding the body’s response to extreme endurance and ensuring the quality of donated blood.

Frequently Asked Questions

What are “omics” markers?

“Omics” markers are biological signals found in blood that can reveal information about a patient’s biological response to injury and treatment.

How accurate is this new prediction method?

In an independent cohort of over 300 trauma patients, the method predicted trauma outcomes with 92% accuracy.

What is the next step in this research?

Researchers are working to adapt their molecular profiling approach for rapid, point-of-care testing in emergency and military settings.

How might earlier, more accurate predictions of recovery impact the way trauma care is delivered in the future?